Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

NCT04965064 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
22
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Rochester